Abstract:The TrkB receptor, which is highly expressed in various human cancers and considered a pro-oncogene, was targeted to develop neutralizing monoclonal antibodies against its immunoglobulin-like (Ig-like) domains. Recombinant TrkB-IgL peptide, including the Ig-like C2 type 1 (Ig-C2-type 1) and Ig-like C2 type 2 (Ig-C2-type 2) domains, was expressed and purified from E. coli. Mice were immunized with this peptide, and hybridoma clones producing anti-TrkB-IgL antibodies were generated. Among 23 ELISA-positive TrkB-IgL hybridoma clones, four (TrkB-IgL 5.11, 4.11, 4.6, 4.3) showed anti-proliferative effects compared to the control on human breast cancer (MCF-7) and human colon cancer (HCT116) cells, as assessed using the xCELLigence system. Western blot analysis revealed that TrkB-IgL 5.11 and 4.11 significantly suppressed TrkB-mediated signaling pathways compared to the control. Purified TrkB-IgL monoclonal antibodies (mAbs) exhibited anti-proliferative effects compared to both positive and negative controls using the xCELLigence system. The TrkB-IgL 5.11 mAb notably suppressed phosphorylation of TrkB, Akt, and ERK and induced Caspase-3 and Caspase-9 activities in a dose-dependent manner, as determined by Western blotting. Additionally, immunostaining confirmed the localization of these mAbs on the SH-SY5Y cell membrane, which is known for high TrkB expression. In conclusion, the TrkB-IgL 5.11 antibody effectively inhibits cancer cell proliferation and induces apoptosis by suppressing key signaling pathways. These findings demonstrate the potential of this antibody as a therapeutic agent for cancers that overexpress TrkB. Additionally, it is considered a promising candidate for humanization, which would facilitate its application in cancer treatment. Supplementary information: The online version contains supplementary material available at 10.1007/s13205-024-04063-x.

A Monoclonal Antibody Against the Extracellular Domain of P75 Neurotrophin Receptor.

Preparation and Identification of Monoclonal Antibody Against Human Testis Development Related Gene 1

Preparation and Application of Monoclonal Antibody Against Hndrg2

Preparation and Characterization of a High-Afﬁnity Monoclonal Antibody Against Nerve Growth Factor

O2‐12‐04: Extracellular Domain of P75ntr Attenuates Beta‐amyloid‐induced Neurotoxicity and Tau Hyperphosphorylation

Preparation and Identification of Monoclonal Antibodies Against Luman-N-term Fusion

Identification of CD73 as the Antigen of an Antigen-Unknown Monoclonal Antibody Established by Exosome Immunization, and Its Antibody–Drug Conjugate Exerts an Antitumor Effect on Glioblastoma Cell Lines

A monoclonal antibody specific for the 200 K polypeptide of the neurofilament triplet.

[Preparation and Biological Activities of Monoclonal Antibody Against P185erbb2].

p75ECD-Fc reverses neonatal hypoxic-ischemic encephalopathy-induced neurological deficits and inhibits apoptosis associated with Nestin

A Monoclonal Antibody Against PMEL.

Preparation, Purification, and Identification of a Monoclonal Antibody Against NRP2 B1b2 Domain.

Developing a novel neutralizing monoclonal antibody against TrkB

Preparation and Identification of a Monoclonal Antibody Against GDDR Protein

Expression,purification and preparation of monoclonal antibody of HCA518 protein

Preparation of the Monoclonal Antibody Against NPM1

[Preparation and Identification of Monoclonal Antibody Against Heterogeneous Nuclear Ribonucleoprotein B1].

Expression of 5T4 extracellular domain fusion protein and preparation of anti-5T4 monoclonal antibody with high affinity and internalization efficiency.

Preparation and identification of monoclonal antibody against human Grn E

Characterization of a monoclonal antibody against CREPT, a novel protein highly expressed in tumors.

Preparation and Identification of Monoclonal Antibody Against Human Atg5